Evidence map›Paper›PMID 34355097›Full record

ArticleHeliyon2021

Zahra Moslemi, Mina Bahrami, Ebrahim Hosseini, Mahboubeh Mansourian, Zahra Daneshyar, Mahdieh Eftekhari, Nasrin Shakerinasab, Arash Asfaram, Esmaeel Panahi Kokhdan, Zahra Barmoudeh and 1 more

Open access · goldAbstract read
In one paragraph

Article in Heliyon, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Antioxidant and hepatoprotective activities ofResearch in pharmaceutical sciences · 2024
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Phytochemical Characteristics and Anti-Inflammatory, Immunoregulatory, and Antioxidant Effects ofEvidence-based complementary and alternative medicine : eCAM · 2023
    Review
  11. Article
  12. Evidence-based complementary and alternative medicine : eCAM · 2022
    Article
  13. Frontiers in microbiology · 2022
    Article
  14. Frontiers in pharmacology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Zahra MoslemiMedicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran.
Mina BahramiMedicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran.
Ebrahim HosseiniMedicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran.
Mahboubeh MansourianMedicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran.
Zahra DaneshyarMedicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran.
Mahdieh EftekhariDepartment of Pharmacognosy and Pharmaceutical Biotechnology, Faculty of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Nasrin ShakerinasabMedicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran.
Arash AsfaramMedicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran.
Esmaeel Panahi KokhdanMedicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran.
Zahra BarmoudehMedicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran.
Amir Hossein DoustimotlaghMedicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran.
Yasuj University of Medical Sciences · IRKermanshah University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCholestasis is a liver disease caused by a malfunction of the hepato-biliary system. Oxidative stress as a systemic complication is the main characteristic of cholestasis. The aim of this study was to evaluate the anti-inflammatory and hepatoprotective effects of MATERIALS AND

methodsTwenty-eight male Wistar rats were randomly divided into four groups: sham control (SC), BDL alone, SC plus 500 mg/kg methanolic extract of PO orally for 1 week, and BDL plus 500 mg/kg methanolic extract of PO orally for 1 week. After 1 week, the animals were anesthetized, and the liver and blood samples were taken from each animal. Biochemical parameters, oxidative stress biomarkers, histopathological changes, as well as the gene expression of IL-1, TNF-α, TGF-β, and α-SMA have been evaluated.

resultsThe methanolic extract of PO at a dose of 500 mg/kg significantly decreased the plasma levels of aminotransferases, alkaline phosphatase as compared to BDL group (P < 0.05), while it had no significant effect on the levels of oxidative stress markers in the hepatic tissue. The plasma level of malondialdehyde and ferric-reducing antioxidant power were markedly elevated in the BDL group in comparison to SC group (P < 0.05), while treatment with PO significantly reduced these markers (P < 0.05). The administration of PO attenuated hydroxyproline content, bile duct proliferation, and inflammation score in the cholestatic liver in contrast to non-treated BDL rats (P < 0.05). Moreover, the methanolic extract of PO markedly declined the expression of TNF-α and TGF-β pro inflammatory genes in contrast to BDL rats.

conclusionsTaken together, our findings showed that

Indexed as

Anti-inflammatory agentsBile ductsCholestasisOxidative stressPortulaca oleraceaRats

Identifiers

PMID34355097
PMCPMC8322275
OpenAlexW3184177036

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.